Format

Send to

Choose Destination
Clin Chim Acta. 2015 Apr 15;444:310-7. doi: 10.1016/j.cca.2014.10.035. Epub 2014 Oct 29.

Thyroglobulin in differentiated thyroid cancer.

Author information

1
Department of Medical Biochemistry & Immunology, University Hospital of Wales, Heath Park, Cardiff CF14 4XW, UK. Electronic address: Carol.evans9@wales.nhs.uk.
2
Department of Medical Biochemistry & Immunology, University Hospital of Wales, Heath Park, Cardiff CF14 4XW, UK.
3
Institute of Genetic Medicine, Newcastle University, Central Parkway, Newcastle upon Tyne, Tyne NE1 3BZ, UK.

Abstract

Identification of differentiated thyroid cancer (DTC) is becoming increasingly common. Patients usually have an excellent prognosis. Most undergo total thyroidectomy, radioiodine ablation and treatment with suppressive doses of levothyroxine. Patients require long term follow-up which includes measurement of serum thyroglobulin (Tg). Interpretation of serum Tg requires knowledge of the concurrent thyroid stimulating hormone (TSH) concentration, as secretion is TSH dependant, and an awareness of the limitations of the methods used to measure it. These limitations include the heterogeneity of Tg in serum, the ability of assays to recognise forms of Tg secreted by a tumour, assay biases and not least the potential for interference in immunoassays for Tg from endogenous thyroglobulin antibodies (TgAbs) in patient serum. This review considers what the clinician wants to know and how Tg results can be interpreted in light of an awareness of assay limitations.

KEYWORDS:

Differentiated thyroid cancer; Thyroglobulin

PMID:
25444737
DOI:
10.1016/j.cca.2014.10.035
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center